- Home
- BRT vs CTNM Comparison
BRT vs CTNM Comparison
Compare BRT & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BRT
- CTNM
- Stock Information
- Founded
- BRT 1972
- CTNM 2009
- Country
- BRT United States
- CTNM United States
- Employees
- BRT N/A
- CTNM N/A
- Industry
- BRT Real Estate Investment Trusts
- CTNM
- Sector
- BRT Real Estate
- CTNM
- Exchange
- BRT Nasdaq
- CTNM Nasdaq
- Market Cap
- BRT 331.7M
- CTNM 199.3M
- IPO Year
- BRT N/A
- CTNM 2024
- Fundamental
- Price
- BRT $18.07
- CTNM $7.14
- Analyst Decision
- BRT Strong Buy
- CTNM Strong Buy
- Analyst Count
- BRT 3
- CTNM 5
- Target Price
- BRT $22.17
- CTNM $24.80
- AVG Volume (30 Days)
- BRT 18.4K
- CTNM 44.8K
- Earning Date
- BRT 05-07-2025
- CTNM 03-06-2025
- Dividend Yield
- BRT 5.57%
- CTNM N/A
- EPS Growth
- BRT N/A
- CTNM N/A
- EPS
- BRT N/A
- CTNM N/A
- Revenue
- BRT $95,630,000.00
- CTNM N/A
- Revenue This Year
- BRT N/A
- CTNM N/A
- Revenue Next Year
- BRT $5.73
- CTNM $108.33
- P/E Ratio
- BRT N/A
- CTNM N/A
- Revenue Growth
- BRT 1.95
- CTNM N/A
- 52 Week Low
- BRT $15.47
- CTNM $5.92
- 52 Week High
- BRT $20.22
- CTNM $22.00
- Technical
- Relative Strength Index (RSI)
- BRT 53.07
- CTNM N/A
- Support Level
- BRT $17.36
- CTNM N/A
- Resistance Level
- BRT $19.01
- CTNM N/A
- Average True Range (ATR)
- BRT 0.53
- CTNM 0.00
- MACD
- BRT 0.05
- CTNM 0.00
- Stochastic Oscillator
- BRT 43.03
- CTNM 0.00
About BRT BRT Apartments Corp. (MD)
BRT Apartments Corp is a real estate investment trust company. The company is primarily focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
About CTNM Contineum Therapeutics Inc. Class A Common Stock
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.